Curis (CRIS) : Traders are bullish on Curis (CRIS) as it has outperformed the S&P 500 by a wide margin of 51.68% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.07%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.24% in the last 1 week, and is up 50.87% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 24.23% and the 50-Day Moving Average is 39.51%.The 200 Day SMA reached 42.34%
Curis (NASDAQ:CRIS): After opening at $2.46, the stock dipped to an intraday low of $2.45 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $2.64 and the buying power remained strong till the end. The stock closed at $2.61 for the day, a gain of 5.67% for the day session. The total traded volume was 1,293,892. The stocks close on the previous trading day was $2.61.
Curis (CRIS) : 2 Wall Street analysts covering Curis (CRIS) believe that the average level the stock could reach for the short term is $5. The maximum price target given is $7 and the minimum target for short term is around $3, hence the standard deviation is calculated at $2.83.
Curis, Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Companys drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis product pipeline also includes CUDC-427, an orally available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma, and human epidermal growth factor receptor 2 (HER 2-), estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Companys PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.